Solara Active Pharma Sciences Ltd.

NSE: SOLARA BSE: 541540 SECTOR: Pharmaceuticals & Drugs  22k   104   20

1019.30
-22.85 (-2.19%)
NSE: 21 Jan 03:54 PM

Price Summary

Today's High

₹ 1042.55

Today's Low

₹ 1015

52 Week High

₹ 1859.95

52 Week Low

₹ 980

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3664 Cr.

Enterprise Value

4072.53 Cr.

No. of Shares

3.59 Cr.

P/E

17.99

P/B

2.2

Face Value

₹ 10

Div. Yield

0.69 %

Book Value (TTM)

₹  463.76

CASH

198.38 Cr.

DEBT

606.91 Cr.

Promoter Holding

39.51 %

EPS (TTM)

₹  56.67

Sales Growth

22.33%

ROE

17.13 %

ROCE

15.28%

Profit Growth

96.43 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year22.33%
3 Year42.36%
5 YearNA

Profit Growth

1 Year96.43%
3 Year383.9%
5 YearNA

ROE%

1 Year17.13%
3 Year12.18%

ROCE %

1 Year15.28%
3 Year12.18%

Debt/Equity

0.3819

Price to Cash Flow

23.72

Interest Cover Ratio

3.61583994317509

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2021 39.51 29.44
Sep 2021 41.07 13.55
Jun 2021 41.07 8.86
Mar 2021 44.11 16.42
Dec 2020 44.13 17.09
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 383.90452507519% for the Past 3 years.
  • The company has shown a good revenue growth of 42.3606225887518% for the Past 3 years.
  • Company’s PEG ratio is 0.384078564313426.
  • The company has an efficient Cash Conversion Cycle of 71.3211870414179 days.

 Limitations

  • Tax rate is low at 0.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • Promoter pledging is high as 29.44%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 397.56 426.69 444.21 405.57 401.61
Total Expenditure 300.41 321.5 344.7 313.71 329.44
Operating Profit 97.15 105.19 99.51 91.86 72.17
Other Income 5.68 8.29 9.86 5.8 3.51
Interest 19.37 20.41 24.86 18.92 17.07
Depreciation 27.52 27.29 27.36 27.6 28.3
Exceptional Items 0 0 0 -0.58 -0.08
Profit Before Tax 55.94 65.78 57.15 50.56 30.23
Tax 0 0 0 0 0
Profit After Tax 55.94 65.78 57.15 50.56 30.23
Adjusted EPS (Rs) 15.62 18.36 15.91 14.08 8.42

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 560.41 1408.58 1321.75 1616.88
Total Expenditure 499.02 1196.3 1065.22 1231.55
Operating Profit 61.39 212.28 256.53 385.33
Other Income 2.29 12.03 27.51 28.41
Interest 25.17 82.48 77.88 84.47
Depreciation 36.56 83.39 93.67 108.31
Exceptional Items 0 0 0 0
Profit Before Tax 1.95 58.44 112.49 220.96
Tax 0 -0.23 0 0
Net Profit 1.95 58.67 112.49 220.96
Adjusted EPS (Rs.) 0.79 22.77 41.9 61.51

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 24.67 25.77 26.85 35.92
Total Reserves 745.19 936.68 1063.94 1556.86
Borrowings 242.86 224.97 232.71 154.83
Other N/C liabilities 72.02 119.03 100.38 51.7
Current liabilities 732.43 650.33 727.73 785.31
Total Liabilities 1817.17 1956.78 2151.61 2584.62
Assets
Net Block 1062.54 1194.74 1374.09 1359.01
Capital WIP 70.31 39.2 40.21 87.72
Intangible WIP 0 0 0 0
Investments 18.53 18.12 18.03 18.13
Loans & Advances 48.23 35.63 39.55 58.95
Other N/C Assets 9.03 19.43 4.38 2.82
Current Assets 608.53 649.66 675.35 1057.99
Total Assets 1817.17 1956.78 2151.61 2584.62
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 1.95 58.44 112.49 220.96
Adjustment 62.33 148.31 167.54 173.16
Changes in Assets & Liabilities -11.67 -26.51 -14.5 -207.11
Tax Paid -2.98 -14.52 -23.51 -32.57
Operating Cash Flow 49.63 165.72 242.02 154.44
Investing Cash Flow -71.12 -112.97 -358.81 -105.25
Financing Cash Flow 67.36 -23 97.01 92.5
Net Cash Flow 45.87 29.75 -19.78 141.69

Corporate Actions

Investors Details

PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Promoters 44.13 44.11 41.07 41.07 39.51
pronomz ventures l... 8.89 8.88 5.90 5.90 5.90
pronomz ventures l... - - - - -
arunkumar pillai - - - - -
arunkumar pillai 8.82 8.82 8.82 8.82 8.81
karuna business so... - - - - -
karuna business so... 7.83 7.83 7.83 7.83 7.82
k r ravishankar 3.69 3.69 3.69 3.69 3.69
srjr enterprise ll... - - - - -
srjr enterprise llp 4.73 4.73 4.73 4.73 4.73
chayadeep ventures... 2.80 2.80 2.80 2.80 2.80
k r ravishankar - - - - -
agnus capital llp 2.37 2.36 2.36 2.36 2.36
chayadeep ventures... - - - - -
agnus capital llp - - - - -
sequent scientific... 1.54 1.54 1.54 1.54 -
chayadeep properti... 1.46 1.46 1.46 1.46 1.46
sequent scientific... - - - - -
chayadeep properti... - - - - -
devicam capital llp 0.42 0.42 0.42 0.42 0.42
devicam capital ll... - - - - -
karuna ventures pr... - 0.29 0.29 0.29 0.29
karuna ventures pr... 0.29 - - - -
karuna ventures pr... - - - - -
agnus holdings pvt... 0.20 0.20 0.20 0.20 0.20
tarini arun kumar 0.15 0.15 0.15 0.15 0.15
aditya arun kumar 0.15 0.15 0.15 0.15 0.15
deepa arun kumar 0.15 0.15 0.15 0.15 0.15
agnus holdings pvt... - - - - -
padmakumar karunak... 0.14 0.14 0.12 0.12 0.12
vineetha mohanakum... 0.14 0.14 0.14 0.14 0.14
deepa arun kumar - - - - -
aditya arun kumar - - - - -
tarini arun kumar - - - - -
vineetha mohanakum... - - - - -
sajitha pillai 0.09 0.09 0.09 0.09 0.09
padmakumar karunak... - - - - -
rajitha gopalakris... 0.08 0.08 0.08 0.08 0.08
hemalatha pillai 0.10 0.10 0.10 0.10 0.10
sajitha pillai - - - - -
k r lakshmi 0.06 0.06 0.06 0.06 0.06
rajitha gopalakris... - - - - -
hemalatha pillai - - - - -
k r lakshmi - - - - -
rajeswari amma - - - - -
triumph venture ho... - - - - -
yalavarthy usha ra... - - - - -
triumph venture ho... 0.02 0.02 - - -
yalavarthy usha ra... 0.02 0.02 - - -
PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Investors 55.87 55.89 58.93 58.93 60.49
tpg growth iv sf p... 15.22 15.22 11.50 11.50 11.49
sbi magnum midcap ... 3.50 3.22 2.11 1.77 1.15
timf holdings 3.01 3.00 3.00 3.00 3.00
bnp paribas arbitr... 2.46 3.50 2.10 2.07 2.00
aditya birla sun l... - - 2.53 2.53 2.59
hbm healthcare inv... - 1.35 1.34 1.34 1.43
shivanand shankar ... - - 2.42 2.42 -
cvr enterprise llp 1.70 1.70 1.70 1.56 1.56
hbm healthcare inv... 1.70 - - - -
unit trust of indi... - - - - -
jitesh devendra 1.84 1.68 1.14 1.08 1.07
raptakos brett & c... 1.39 1.39 1.31 1.19 1.18
route one offshore... - - - - -
the scottish orien... - - 1.11 1.11 1.58
sequent scientific... - - - - 1.54
caisse de depot et... - - - - 1.49
route one offshore... 1.25 - - - -
route one offshore... - 1.25 1.25 1.25 1.25
first state indian... - - - - 1.24
kotak mahindra tru... - - - - 1.03
iepf 0.02 0.02 0.02 0.02 0.02

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ2FY20 9 Jan 2020
  • PresentationQ2FY21 18 Nov 2020
  • PresentationQ1FY21 18 Nov 2020
  • PresentationQ2FY22 15 Nov 2021
  • PresentationQ4FY21 12 Apr 2021

Company News

Solara Active Pharma Sciences informs about disclosures11 Jan 2022, 2:36PM Solara Active Pharma Sciences informs about disclosure2 Dec 2021, 4:59PM Solara Active Pharma Sciences informs about outcome of board meeting11 Nov 2021, 4:51PM Solara Active Pharma Sciences informs disclosure8 Nov 2021, 4:12PM Solara Active Pharma Sciences informs about issuance of duplicate share certificate13 Oct 2021, 4:29PM Solara Active Pharma Sciences informs about newspaper publication20 Sep 2021, 2:53PM Solara Active Pharma Sciences informs about disclosure13 Sep 2021, 4:43PM Solara Active Pharma Sciences informs about outcome of circular resolution 19 Aug 2021, 9:46AM Solara Active Pharma Sciences informs about investor presentation 28 Jul 2021, 1:08PM Solara Active Pharma Sciences informs about disclosure of related party transactions3 Jun 2021, 4:37PM Solara Active Pharma Science informs about virtual investor conference19 May 2021, 11:44AM Solara Active Pharma Sciences informs about disclosure11 May 2021, 5:21PM Solara Active Pharma Sciences informs about newspaper advertisement7 May 2021, 4:14PM Solara Active Pharma Sciences submits investor presentation 10 Apr 2021, 11:17AM Solara Active Pharma, Aurore Life Sciences combine to create second largest Pure Play API / CRAMs company in India10 Apr 2021, 9:37AM Solara Active Pharma Science informs about updates16 Mar 2021, 12:09PM Solara Active Pharma Science informs about disclosure22 Feb 2021, 4:28PM Solara Active Pharma Sciences informs about newspaper publication 13 Feb 2021, 11:25AM Solara Active Pharma Science informs about change of RTA 17 Dec 2020, 11:38AM Solara Active Pharma Science informs about disclosure of related party transactions19 Nov 2020, 10:36AM Solara Active Pharma Sciences informs about virtual meeting25 Sep 2020, 4:12PM CRISIL upgrades ratings of Solara Active Pharma Sciences25 Sep 2020, 4:03PM Solara Active Pharma Sciences reports 59% rise in Q1 consolidated net profit4 Aug 2020, 10:46AM Solara Active Pharma Sciences informs about newspaper advertisement 4 Jul 2020, 2:27PM Solara Active Pharma Science informs about board meeting4 May 2020, 10:37AM

Solara Active Pharma Stock Price Analysis and Quick Research Report. Is Solara Active Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Solara Active Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 154.44 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Solara Active Pharma has a Debt to Equity ratio of 0.3819 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Solara Active Pharma , the EPS growth was 46.8276021961665 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Solara Active Pharma has OPM of 23.8317005591015 % which is a good sign for profitability.
     
  • ROE: Solara Active Pharma have a average ROE of 17.1349915666621 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Solara Active Pharma

X